Cover Image
市場調查報告書

先天性水皰症:開發中產品分析

Epidermolysis Bullosa - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213080
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
先天性水皰症:開發中產品分析 Epidermolysis Bullosa - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 90 Pages
簡介

先天性水皰症是先天水皰症障礙的一種,其特徵為對無意識外傷反應而形成水皰。主要的症狀有皮膚上的水皰形成、手指及指甲的畸形、損失、體內(喉嚨、食道、上部氣管、胃、腸、尿道等)形成水皰、手掌及腳掌皮膚的增厚化(角質增殖症)、頭皮出現水皰、疤痕化、毛髮脫落等。主要治療方法有抗生素及外科手術等。

本報告提供全球各國治療先天性水皰症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

先天性水皰症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

先天性水皰症:企業開發中的治療藥

先天性水皰症:大學/機關研究中的治療藥

先天性水皰症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

先天性水皰症:企業開發中的產品

先天性水皰症:大學/機關研究中的產品

先天性水皰症的治療藥開發企業

  • Birken AG
  • Fibrocell Science, Inc.
  • GlaxoSmithKline Plc
  • InMed Pharmaceuticals Inc.
  • Karus Therapeutics Limited
  • ProQR Therapeutics N.V.
  • RegeneRx Biopharmaceuticals, Inc.
  • Scioderm, Inc.
  • Stratatech Corporation
  • TWi Pharmaceuticals, Inc.
  • WAVE Life Sciences Ltd.

先天性水皰症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

先天性水皰症:最近的開發平台趨勢

先天性水皰症:暫停中的計劃

先天性水皰症:開發中止的產品

先天性水皰症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8581IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Pipeline Review, H2 2016, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.

Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 1, 8 and 4 respectively for Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively for Epidermolysis Bullosa.

Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Epidermolysis Bullosa Overview
  • Therapeutics Development
    • Pipeline Products for Epidermolysis Bullosa - Overview
    • Pipeline Products for Epidermolysis Bullosa - Comparative Analysis
  • Epidermolysis Bullosa - Therapeutics under Development by Companies
  • Epidermolysis Bullosa - Therapeutics under Investigation by Universities/Institutes
  • Epidermolysis Bullosa - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Epidermolysis Bullosa - Products under Development by Companies
  • Epidermolysis Bullosa - Products under Investigation by Universities/Institutes
  • Epidermolysis Bullosa - Companies Involved in Therapeutics Development
    • Abeona Therapeutics, Inc.
    • Amryt Pharma plc
    • Berg LLC
    • Fibrocell Science, Inc.
    • GlaxoSmithKline Plc
    • InMed Pharmaceuticals Inc.
    • Karus Therapeutics Limited
    • ProQR Therapeutics N.V.
    • RegeneRx Biopharmaceuticals, Inc.
    • Scioderm, Inc.
    • Stratatech Corp
    • TWi Pharmaceuticals, Inc.
    • WAVE Life Sciences Ltd.
  • Epidermolysis Bullosa - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • allantoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALLO-ASC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide 1 to Inhibit Keratin for Epidermolysis Bullosa Simplex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide 2 to Inhibit Keratin for Epidermolysis Bullosa Simplex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • birch bark extract - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Dermatology and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diacerein - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EB-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EB-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FCX-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ICX-RHY - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INM-750 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KA-1463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QR-313 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RGN-137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TXA-127 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ubidecarenone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Epidermolysis Bullosa - Dormant Projects
  • Epidermolysis Bullosa - Discontinued Products
  • Epidermolysis Bullosa - Product Development Milestones
    • Featured News & Press Releases
      • Oct 01, 2016: Castle Creek Pharmaceuticals Announces Late-Breaking Results at EADV of Phase 2 Topical Diacerein 1% Data in Patients with Epidermolysis Bullosa Simplex
      • Sep 26, 2016: Abeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
      • Sep 19, 2016: Fibrocell Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
      • Sep 13, 2016: Amryt Pharma announces US patent for Lead Drug, Episalvan
      • Sep 08, 2016: Abeona Therapeutics Enrolls 5th Patient in Phase 1/2 Gene Therapy Clinical Trial for Epidermolysis Bullosa
      • Sep 07, 2016: Tarix Orphan Receives Orphan Drug Status for TXA127 for Genetic Skin Disorder Recessive Dystrophic Epidermolysis Bullosa
      • Jul 27, 2016: Fibrocell Announces First Subjects Enrolled in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
      • Jun 29, 2016: Fibrocell Announces Update on FCX-007
      • Jun 27, 2016: Tarix Orphan Announces Positive Results with TXA127 in Animal Model of Dystrophic Epidermolysis Bullosa
      • Jun 13, 2016: Fibrocell Announces Initiation of Patient Recruitment in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
      • Apr 18, 2016: Fibrocell and Intrexon Announce Allowance to Commence Phase I/II Trial for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
      • Dec 04, 2015: RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment
      • Oct 08, 2015: Fibrocell and Intrexon Announce Poster Presentation on FCX-007 for the Treatment of RDEB at American Society of Human Genetics Annual Meeting
      • Sep 25, 2015: Fibrocell and Intrexon Provide Regulatory Update for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
      • Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Epidermolysis Bullosa, H2 2016
  • Number of Products under Development for Epidermolysis Bullosa - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Epidermolysis Bullosa - Pipeline by Abeona Therapeutics, Inc. , H2 2016
  • Epidermolysis Bullosa - Pipeline by Amryt Pharma plc, H2 2016
  • Epidermolysis Bullosa - Pipeline by Berg LLC, H2 2016
  • Epidermolysis Bullosa - Pipeline by Fibrocell Science, Inc., H2 2016
  • Epidermolysis Bullosa - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc., H2 2016
  • Epidermolysis Bullosa - Pipeline by Karus Therapeutics Limited, H2 2016
  • Epidermolysis Bullosa - Pipeline by ProQR Therapeutics N.V., H2 2016
  • Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016
  • Epidermolysis Bullosa - Pipeline by Scioderm, Inc., H2 2016
  • Epidermolysis Bullosa - Pipeline by Stratatech Corp, H2 2016
  • Epidermolysis Bullosa - Pipeline by TWi Pharmaceuticals, Inc., H2 2016
  • Epidermolysis Bullosa - Pipeline by WAVE Life Sciences Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Epidermolysis Bullosa - Dormant Projects, H2 2016
  • Epidermolysis Bullosa - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Epidermolysis Bullosa, H2 2016
  • Number of Products under Development for Epidermolysis Bullosa - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top